Key result
Post-discharge beta-blockers cut all-cause mortality ~30% vs non-use in AMI patients.
Why the study?
The effect of beta-blocker use after discharge on patients with AMI in the contemporary reperfusion era remains ambiguous.
Does beta-blocker use after discharge reduce all-cause mortality in patients with acute myocardial infarction in the contemporary reperfusion era?
Meta-Analysis (n=47,339)
Does beta-blocker use after discharge reduce all-cause mortality in patients with acute myocardial infarction in the contemporary reperfusion era?
Beta-blocker use after discharge in the contemporary reperfusion era is associated with reduced all-cause mortality, cardiac death, and recurrent MI in AMI patients, including those with preserved left ventricular function.
Answers are grounded in this paper and cite their sources.
Supports beta-blocker use post-AMI discharge; extends evidence to preserved LVEF in the reperfusion era.
Background and objectives: The effect of beta-blocker use after discharge on patients with acute myocardial infarction (AMI) in the contemporary reperfusion era remains ambiguous. By applying meta-analysis, we sought to assess the role of beta-blockers in the contemporary reperfusion era. Materials and Methods: Randomized controlled trials (RCT) and observational studies using propensity score matching, comparing use of beta-blockers with non-use of beta-blockers, in patients with AMI after discharge. The primary outcome was all-cause mortality. Odds ratios (OR) and associated 95% confidence intervals (CI) were calculated. Results: One RCT and eight observational studies, containing 47,339 patients with AMI, were included. Compared with non-use of beta-blockers, beta-blocker use after discharge may have reduced the risk of all-cause mortality (OR: 0.70, 95% CI: 0.61 to 0.80, I2 = 14.4%), cardiac death (OR: 0.63, 95% CI: 0.44 to 0.91, I2 = 22.8%), myocardial infarction (OR: 0.73, 95% CI: 0.62 to 0.86, I2 = 0), and revascularization (OR: 0.92, 95% CI: 0.85 to 0.99, I2 = 0). No significant differences were found in major adverse cardiovascular events (MACE, OR: 0.88, 95% CI: 0.66 to 1.17, I2 = 78.4%), heart failure (OR: 0.56, 95% CI: 0.29 to 1.08, I2 = 0) or stroke (OR: 1.13, 95% CI: 0.92 to 1.39, I2 = 0). For patients with preserved left ventricular function, beta-blocker use after discharge may have also reduced the risk of all-cause mortality (OR: 0.61, 95% CI: 0.44 to 0.84, I2 = 0). Conclusions: Use of beta-blockers after discharge may still be beneficial for AMI patients in the contemporary reperfusion era, with or without preserved left ventricular function.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2022) conducted a meta-analysis in Acute myocardial infarction (n=47,339). Beta-blockers vs. Non-use of beta-blockers was evaluated on All-cause mortality (OR 0.70, 95% CI 0.61 to 0.80). Beta-blocker use after discharge in patients with acute myocardial infarction reduced the risk of all-cause mortality compared with non-use.
Synapse has enriched 10 related papers. Consider them for comparative context: